Cadrenal Therapeutics, Inc.
(Note: Cadrenal Therapeutics Inc. priced its IPO on Jan. 19, 2023, in sync with the terms in its prospectus: 1.4 million shares at $5.00 to raise $7.0 million. Cadrenal Therapeutics, Inc. added Sutter Securities as a joint book-runner with Boustead Securities (previously sole book-runner) in an S-1/A filing dated Dec. 8, 2022. Previously: Cadrenal Therapeutics […]
September 23, 2022 Read More